Skip to content
Parakho

Alkem Laboratories Ltd

NSE ALKEMBSE 539523

Q1 FY27, unaudited

Revenue
₹2,667.73 Cr
Profit after tax
₹569.98 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations2,667.73+12.46%9,663.91
Other income136.62+17.19%555.17
Total income2,804.35+12.68%10,219.08
Employee benefit expense547.47+16.55%1,883.03
Finance costs17.52+36.98%57.29
Depreciation & amortisation57.22−2.84%256.56
Total expenses2,005.93+10.01%7,553.37
Profit before tax798.42+17.47%2,522.62
Tax expense228.44+297.91%337.50
Profit after tax569.98−13.13%2,282.09
Total comprehensive income567.42−13.24%2,286.71
Earnings per share
Earnings per share, basic₹47.67₹190.87
Earnings per share, diluted₹47.67₹190.87

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Alkem Laboratories reported Q4 FY26 revenue of INR36,033 million, up 14.6% year-on-year, with EBITDA margin at 14.4% versus 12.4% in the prior year quarter. For FY26, total revenue from operations was INR1,47,123 million, up 13.5%, with EBITDA margin at 20.4% versus 19.4% in FY25. Management discussed the semaglutide launch, the Occlutech acquisition, cost pressures from geopolitical and supply-chain factors, and the planned transition of CEO Vikas Gupta.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 58 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 20 Aug 2026.